alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Full Employment and Balanced Growth Act of 1976

              																	United States. Congress. Senate. Committee on Banking, Housing, and Urban Affairs, 1970-					,	Proxmire, William					 and 	Ninety-Fourth Congress, 1975-1977. 						*Full Employment and Balanced Growth Act of 1976 : Hearings Before the Committee on Banking, Housing, and Urban Affairs, United States Senate, Ninety-Fourth Congress, Second Session, on S. 50, May 20, 21, and 25, 1976*,												Washington: 								U.S. Government Printing Office, 										May 20, 21, and 25, 1976,									https://fraser.stlouisfed.org/title/1087,			accessed on September 11, 2024.						    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
# Third District Court of Appeal State of Florida Opinion filed November 16, 2022. Not final until disposition of timely filed motion for rehearing.

________________ No. 3D22-1112 Lower Tribunal No. F20-10705

________________ Guy Greene II, 

### Appellant,
vs. The State of Florida, 

### Appellee.
An Appeal from the Circuit Court for Miami-Dade County, Teresa Pooler, Judge. Carlos J. Martinez, Public Defender, and Andrew Stanton, Assistant Public Defender, for appellant. Ashley Moody, Attorney General, and Linda Katz, Assistant Attorney General, for appellee. Before HENDON, MILLER and BOKOR, JJ. PER CURIAM. Affirmed.
Order entered May 29, 2015

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-15-00054-CV

BARBARA MEREDITH, Appellant

V.

OXFORD TOWNHOMES, LLC, ET AL., Appellees

On Appeal from the County Court at Law No. 2

Dallas County, Texas

Trial Court Cause No. CC-10-07847-B

ORDER

We GRANT appellant’s May 27, 2015 unopposed motion for an extension of time to file 

a brief. Appellant shall file a brief by JUNE 26, 2015.

We GRANT cross-appellant Oxford Townhomes Addition Homeowner’s Association, 

Inc.’s May 27, 2015 unopposed motion for an extension of time to file a brief. Cross-appellant 

shall file a brief by JUNE 8, 2015.

/s/ ELIZABETH LANG-MIERS 

JUSTICE
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Consumer Product Safety Commission

# TIME AND DATE:

Wednesday, March 3, 2010; 2 p.m.

# Place:

Hearing Room 420, Bethesda Towers, 4330 East-West Highway, Bethesda, Maryland.

# Status:

Closed to the Public.

# MATTERS TO BE CONSIDERED:

## Compliance Status Report

The Commission staff will brief the Commission on the status of compliance matters.

For a recorded message containing the latest agenda information, call (301) 504-7948.

# CONTACT PERSON FOR MORE INFORMATION:

Todd A. Stevenson, Office of the Secretary, U.S. Consumer Product Safety Commission, 4330 East-West Highway, Bethesda, MD 20814, (301) 504-7923.

Dated: February 22, 2010.

Todd A. Stevenson,

Secretary.

[FR Doc. 2010-4028 Filed 3-1-10; 8:45 am]

BILLING CODE 6355-01-M
<PAGE>
                                                                    Exhibit 14.2

                    [Letterhead of Deloitte Touche Tohmatsu]

            CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements on
Form S-8 ((File Nos. 33-97162, 333-07946 and 333-110236) of Deswell Industries,
Inc. of our report dated June 28, 2002, relating to the consolidated statements
of income, shareholders' equity and cash flows of Deswell Industries, Inc. and
its subsidiaries for the year ended March 31, 2002 (which expresses an
unqualified opinion and includes modifications to the first paragraph concerning
the inclusion of the disclosures required by Statement of Financial Accounting
Standards No. 142 "Goodwill and Other Intangible Assets" included in Note 2 and
the revisions to related per share and number of shares information as a result
of the three-for-two stock split described in Note 11 to the consolidated
financial statements), appearing in the annual report on Form 20-F of Deswell
Industries, Inc. for the year ended March 31, 2002.

/s/ Deloitte Touche Tohmatsu

Hong Kong
July 16, 2004
§ 814.46 Withdrawal of approval of a PMA. ( a ) FDA may issue an order withdrawing approval of a PMA if, from any information available to the agency, FDA determines that: ( 1 ) Any of the grounds under section 515(e)(1) (A)-(G) of the act applies.
( 2 ) Any postapproval requirement imposed by the PMA approval order or by regulation has not been met.
( 3 ) A nonclinical laboratory study that is described in the PMA and that is essential to show that the device is safe for use under the conditions prescribed, recommended, or suggested in its proposed labeling, was not conducted in compliance with the good laboratory practice regulations in part 58 and no reason for the noncompliance is provided or, if it is, the differences between the practices used in conducting the study and the good laboratory practice regulations do not support the validity of the study.
( 4 ) Any clinical investigation involving human subjects described in the PMA, subject to the institutional review board regulations in part 56 of this chapter or informed consent regulations in part 50 of this chapter or GCP referenced in § 814.15(a) and described in § 812.28(a) of this chapter, was not conducted in compliance with those regulations such that the rights or safety of human subjects were not adequately protected or the supporting data were determined to be otherwise unreliable.
( b ) ( 1 ) FDA may seek advice on scientific matters from any appropriate FDA advisory committee in deciding whether to withdraw approval of a PMA.
( 2 ) FDA may use information other than that submitted by the applicant in deciding whether to withdraw approval of a PMA.
( c ) Before issuing an order withdrawing approval of a PMA, FDA will issue the holder of the approved application a notice of opportunity for an informal hearing under part 16.
( d ) If the applicant does not request a hearing or if after the part 16 hearing is held the agency decides to proceed with the withdrawal, FDA will issue to the holder of the approved application an order withdrawing approval of the application. The order will be issued under § 814.17, will state each ground for withdrawing approval, and will include a notice of an opportunity for administrative review under section 515(e)(2) of the act.
( e ) FDA will give the public notice of an order withdrawing approval of a PMA. The notice will be published in the Federal Register and will state that a detailed summary of information respecting the safety and effectiveness of the device, including information about any adverse effects of the device on health, has been placed on public display and that copies are available upon request. When a notice of withdrawal of approval is published, data and information in the PMA file will be available for public disclosure in accordance with § 814.9.
[51 FR 26364, July 22, 1986, as amended at 83 FR 7387, Feb. 21, 2018]
§ 807.37 Public availability of establishment registration and device listing information. ( a ) Establishment registration and device listing information is available for public inspection in accordance with section 510(f) of the Federal Food, Drug, and Cosmetic Act and will be posted on the FDA website, with the exception of the information identified in paragraph (b) of this section. Requests for information by persons who do not have access to the internet should be directed to the Imports and Registration and Listing Team, Division of Regulatory Programs 2, Office of Regulatory Programs, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm.1432, Silver Spring, MD 20993-0002. In addition, there will be available for inspection at each of the Food and Drug Administration district offices the same information for firms within the geographical area of such district offices. Upon request, verification of a registration number or location of a registered establishment will be provided.
( b ) The following listing information will not be available for public inspection or posted on the FDA Web site: ( 1 ) For contract manufacturers, contract sterilizers, and private label manufacturers, the proprietary or brand name(s) under which a device is marketed and the FDA-assigned premarket submission number, if this information would reveal a confidential business relationship;
( 2 ) FDA-assigned listing numbers.
[77 FR 45943, Aug. 2, 2012, as amended at 85 FR 18442, Apr. 2, 2020]
§ 573.120 Acrylamide-acrylic acid resin. Acrylamide-acrylic acid resin (hydrolized polyacrylamide), only for the purposes of this section as described below, may be safely used in accordance with the following prescribed conditions: ( a ) The additive is produced by polymerization of acrylamide with partial hydrolysis, or by copolymerization of acrylamide and acrylic acid with the greater part of the polymer being composed of acrylamide units.
( b ) The additive meets the following specifications: ( 1 ) A minimum molecular weight of 3 million.
( 2 ) Viscosity range: 3,000 to 6,000 centipoises at 77 °F in a 1 percent aqueous solution as determined by LVF Brookfield Viscometer or equivalent using a number 6 spindle at 20 r.p.m.
( 3 ) Residual acrylamide: Not more than 0.05 percent.
( c ) It is used as a thickener and suspending agent in nonmedicated aqueous suspensions intended for addition to animal feeds.
[41 FR 38652, Sept. 10, 1976, as amended at 45 FR 38058, June 6, 1980]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          APR-30-2000
<PERIOD-END>                               JUL-31-1999
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                  539,482
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               540,882
<PP&E>                                       6,799,873
<DEPRECIATION>                             (1,517,533)
<TOTAL-ASSETS>                               6,045,137
<CURRENT-LIABILITIES>                        1,458,296
<BONDS>                                      3,670,339
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    24,109,971
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                 6,045,137
<SALES>                                              0
<TOTAL-REVENUES>                               603,649
<CGS>                                                0
<TOTAL-COSTS>                                  267,960
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              54,690
<INCOME-PRETAX>                              (368,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (368,000)
<EPS-BASIC>                                      (.06)
<EPS-DILUTED>                                    (.06)


</TABLE>
Exhibit 4.7

CONFIDENTIAL TREATMENT REQUESTEDSchedule 1 to Exhibit 4.6  Individual Deviations from Standard Non-Compete Agreement by Members of the Management Board(1)

Name

For reporting
period

Geographic
scope; §1

Industry
scope; §1

Term; §1

Compensation;
§2

Deducted
payments;
§2

Penalty; §5Kai-Uwe Ricke

1.1. to 31.12.2004Dr. Karl-Gerhard Eick

1.1. to 31.12.2004Dr. Heinz Klinkhammer(2)

1.1. to 31.12.2004

Confidential material redacted and filed separatelywith the CommissionRené Oberman

1.1. to 31.12.2004Konrad F. Reiss

1.1. to 31.12.2004Walter Raizner

1.1. to 31.12.2004


---

---



QuickLinks
# C_2019216EN.01000101.xml

| 27.6.2019 | EN | Official Journal of the European Union | C 216/1 |
| --- | --- | --- | --- |

27.6.2019

EN

Official Journal of the European Union

C 216/1

---

COUNCIL DECISION

of 25 June 2019

appointing the members and alternate members of the Management Board of the European Foundation for the Improvement of Living and Working Conditions (Eurofound) for Lithuania, Luxembourg and Slovenia

(2019/C 216/01)

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) 2019/127 of the European Parliament and of the Council of 16 January 2019 establishing the European Foundation for the improvement of living and working conditions (Eurofound) (1), and in particular Article 4 thereof,

Having regard to the lists of nominations for appointment submitted to the Council by the Governments of the Member States and by the employees' and the employers' organisations,

Whereas:

| (1) | By its Decision of 9 April 2019 (2), the Council appointed the members and alternate members of the Management Board of the European Foundation for the Improvement of Living and Working Conditions (Eurofound) for the period from 1 April 2019 to 31 March 2023. |
| --- | --- |

(1)

By its Decision of 9 April 2019 (2), the Council appointed the members and alternate members of the Management Board of the European Foundation for the Improvement of Living and Working Conditions (Eurofound) for the period from 1 April 2019 to 31 March 2023.

| (2) | The government of Luxembourg and the employers' organisation BusinessEurope have submitted nominations for several posts to be filled, |
| --- | --- |

(2)

The government of Luxembourg and the employers' organisation BusinessEurope have submitted nominations for several posts to be filled,

HAS ADOPTED THIS DECISION:

Article 1

The following are hereby appointed members and alternate members of the Management Board of the European Foundation for the Improvement of Living and Working Conditions (Eurofound) for the period ending on 31 March 2023:

I.   GOVERNMENT REPRESENTATIVES

| Country | Members | Alternate members |
| --- | --- | --- |
| Luxembourg | Ms Nadine WELTER | Mr Gary TUNSCH |

Country

Members

Alternate members

Luxembourg

Ms Nadine WELTER

Mr Gary TUNSCH

II.   REPRESENTATIVES OF EMPLOYERS' ORGANISATIONS

| Country | Members | Alternate members |
| --- | --- | --- |
| Lithuania | | Mr Ričardas SARTATAVIČIUS |
| Slovenia | Mr Jože SMOLE | Mr Igor ANTAUER |

Country

Members

Alternate members

Lithuania

Mr Ričardas SARTATAVIČIUS

Slovenia

Mr Jože SMOLE

Mr Igor ANTAUER

Article 2

The Council shall appoint the members and alternate members not yet nominated at a later date.

Article 3

This Decision shall enter into force on the date of its adoption.

Done at Luxembourg, 25 June 2019.

For the Council

The President

A. ANTON

---

(1)  OJ L 30, 31.1.2019, p. 74.

1

(2)  OJ C 135, 11.4.2019, p. 1.

2

---
§ 501.110 Animal feed labeling; collective names for feed ingredients. ( a ) An animal feed shall be exempt from the requirements of section 403(i)(2) of the act with respect to its label bearing the common or usual names of the animal feed ingredients listed in paragraph (b) of this section under the following prescribed conditions: ( 1 ) The animal feed is intended solely for livestock and poultry.
( 2 ) The label of the animal feed bears the collective name(s) prescribed in paragraph (b) of this section in lieu of the corresponding common or usual names of the individual feed ingredients contained therein.
( 3 ) The label of the animal feed otherwise conforms to the requirements of section 403(i)(2) of the act.
( 4 ) The ingredients of any feed listed in paragraph (b) of this section neither contain nor are food additives as defined in section 201(s) of the act unless provided for by and in conformity with applicable regulations established pursuant to section 409 of the act.
( b ) Each collective name referred to in this paragraph may be used for the purpose of labeling where one or more of the ingredients listed for that collective name are present. The animal feed ingredients listed under each of the collective names are the products defined by the Association of American Feed Control Officials. The collective names are as follows: ( 1 ) *Animal protein products* include one or more of the following: Animal products, marine products, and milk products.
( 2 ) *Forage products* include one or more of the following: Alfalfa meals, entire plant meals, hays, and stem meals.
( 3 ) *Grain products* include one or more of the following: Barley, grain sorghums, maize (corn), oats, rice, rye, and wheat.
( 4 ) *Plant protein products* include one or more of the following: Algae meals, coconut meals (copra), cottonseed meals, guar meal, linseed meals, peanut meals, safflower meals, soybean meals, sunflower meals, and yeasts.
( 5 ) *Processed grain byproducts* include one or more of the following: Brans, brewers dried grains, distillers grains, distillers solubles, flours, germ meals, gluten feeds, gluten meals, grits, groats, hominy feeds, malt sprouts, middlings, pearled, polishings, shorts, and wheat mill run.
( 6 ) *Roughage products* include one or more of the following: Cobs, hulls, husks, pulps, and straws.
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM (A)
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR 3 MONTHS ENDING MARCH
28, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH (B) FORM 10-Q FOR
THE QUARTER ENDED MARCH 28, 1999.
</LEGEND>
<CIK> 0000813856
<NAME> PRANDIUM, INC.
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-26-1999
<PERIOD-START>                             DEC-28-1998
<PERIOD-END>                               MAR-28-1999
<CASH>                                           7,309
<SECURITIES>                                         0
<RECEIVABLES>                                    5,264
<ALLOWANCES>                                         0
<INVENTORY>                                      4,598
<CURRENT-ASSETS>                                20,939
<PP&E>                                         290,515
<DEPRECIATION>                                  90,569
<TOTAL-ASSETS>                                 329,458
<CURRENT-LIABILITIES>                          115,391
<BONDS>                                        239,950
<PREFERRED-MANDATORY>                            1,804
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                    (31,322)
<TOTAL-LIABILITY-AND-EQUITY>                   329,458
<SALES>                                        134,258
<TOTAL-REVENUES>                               134,258
<CGS>                                           35,721
<TOTAL-COSTS>                                  135,232
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               7,283
<INCOME-PRETAX>                                (8,257)
<INCOME-TAX>                                       147
<INCOME-CONTINUING>                            (8,404)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (8,404)
<EPS-PRIMARY>                                   (0.05)
<EPS-DILUTED>                                   (0.05)
        

</TABLE>
# C_2015118EN.01001102.xml

| 13.4.2015 | EN | Official Journal of the European Union | C 118/11 |
| --- | --- | --- | --- |

13.4.2015

EN

Official Journal of the European Union

C 118/11

---

Appeal brought on 29 August 2014 by Romano Pisciotti against the order of the General Court (Second Chamber) delivered on 2 July 2014 in Case T-403/14 Pisciotti v Commission

(Case C-411/14 P)

(2015/C 118/15)

Language of the case: Italian

Parties

Parties

Appellant: Romano Pisciotti (represented by: M. Maresca, avvocato)

Appellant:

Other party to the proceedings: European Commission

Other party to the proceedings:

By order of 28 January 2015, the Court (Second Chamber) dismissed the appeal and ordered Mr Romano Pisciotti to bear his own costs.

---
§ 522.454 Clodronate. ( a ) *Specifications.* Each milliliter of solution contains 60 milligrams (mg) clodronate disodium.
( b ) *Sponsor.* See No. 043264 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 1.8 mg per kilogram of body weight by intramuscular injection up to a maximum dose of 900 mg per horse.
( 2 ) *Indications for use.* For the control of clinical signs associated with navicular syndrome.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 37620, July 2, 2014]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1140 Calcitonin test system. ( a ) *Identification.* A calcitonin test system is a device intended to measure the thyroid hormone calcitonin (thyrocalcitonin) levels in plasma and serum. Calcitonin measurements are used in the diagnosis and treatment of diseases involving the thyroid and parathyroid glands, including carcinoma and hyperparathyroidism (excessive activity of the parathyroid gland).
( b ) *Classification.* Class II.